Infectious diseases of bacterial origin currently account for the greatest number of human deaths worldwide, serving as a major hurdle for the growth of many developing nations including the Indian subcontinent. However, identification of potential therapeutic drug targets in infectious pathogens, to facilitate species-selective and target-specific inhibition for the development of effective therapeutic regimens, involves several challenges ranging from the identification and validation of a suitable drug target to overcoming drug toxicity and antimicrobial resistance. This short review is a compilation of a decade of research on the potential antibacterial drug target inosine-5′-monophosphate dehydrogenase (IMPDH) and its therapeutic implications for microbial infections.
{"title":"IMPDH as a potential antibacterial drug target for microbial infections: A review on a decade of targeted therapy and its implications","authors":"Haritha Dilip , Shalini , Vijay Thiruvenkatam , Sivapriya Kirubakaran","doi":"10.1016/j.drudis.2025.104505","DOIUrl":"10.1016/j.drudis.2025.104505","url":null,"abstract":"<div><div>Infectious diseases of bacterial origin currently account for the greatest number of human deaths worldwide, serving as a major hurdle for the growth of many developing nations including the Indian subcontinent. However, identification of potential therapeutic drug targets in infectious pathogens, to facilitate species-selective and target-specific inhibition for the development of effective therapeutic regimens, involves several challenges ranging from the identification and validation of a suitable drug target to overcoming drug toxicity and antimicrobial resistance. This short review is a compilation of a decade of research on the potential antibacterial drug target inosine-5′-monophosphate dehydrogenase (IMPDH) and its therapeutic implications for microbial infections.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 11","pages":"Article 104505"},"PeriodicalIF":7.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145327981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.drudis.2025.104524
Lisa Blank , Giulia Pander , Eric Mühlberg , Walter Mier , Philipp Uhl
Nanobodies (Nbs) are genetically engineered single domain antibodies derived from heavy chain-only antibodies (HcAbs) found in camelid species. These monomeric antibody fragments are smaller and have lower molecular weight compared with conventional antibodies, while retaining full antigen-binding specificity, endowing them with unique structural and functional properties. As in vitro diagnostics, they can aid pathogen detection and biomarker identification. In vivo, their rapid clearance and deep tissue penetration enable radio-imaging with short half-life radionuclides, reducing patient exposure. Therapeutically, Nbs are being explored for cancer, neurodegenerative, and infectious diseases. However, their short serum half-life is challenging, prompting strategies to extend circulation time without compromising their benefits. Despite these hurdles, the high specificity, low immunogenicity, and versatility of Nbs position them as promising tools across diverse applications.
{"title":"Exploiting the unique properties of nanobodies: enhancing therapeutics, drug delivery, and targeted diagnostics","authors":"Lisa Blank , Giulia Pander , Eric Mühlberg , Walter Mier , Philipp Uhl","doi":"10.1016/j.drudis.2025.104524","DOIUrl":"10.1016/j.drudis.2025.104524","url":null,"abstract":"<div><div>Nanobodies (Nbs) are genetically engineered single domain antibodies derived from heavy chain-only antibodies (HcAbs) found in camelid species. These monomeric antibody fragments are smaller and have lower molecular weight compared with conventional antibodies, while retaining full antigen-binding specificity, endowing them with unique structural and functional properties. As <em>in vitro</em> diagnostics, they can aid pathogen detection and biomarker identification. <em>In vivo</em>, their rapid clearance and deep tissue penetration enable radio-imaging with short half-life radionuclides, reducing patient exposure. Therapeutically, Nbs are being explored for cancer, neurodegenerative, and infectious diseases. However, their short serum half-life is challenging, prompting strategies to extend circulation time without compromising their benefits. Despite these hurdles, the high specificity, low immunogenicity, and versatility of Nbs position them as promising tools across diverse applications.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 12","pages":"Article 104524"},"PeriodicalIF":7.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145436663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.drudis.2025.104520
Yun Wan , Makoto Nakayama , Cesar Floyd Aldana , Frank Alvino
Persona-driven generative artificial intelligence (GenAI) represents a transformative approach to pharmaceutical innovation, providing structured frameworks that enhance AI–human collaboration across drug development. We examine recent applications (2023–2025) spanning target identification, clinical development, regulatory intelligence, and patient communication. Key developments include AlphaFold 3’s protein structure prediction breakthroughs, regulatory validation of digital twin methodologies, and AI-powered regulatory intelligence systems. Using contextual priming and specialized domain expertise, personas significantly improve GenAI performance in pharmaceutical contexts. Although these tools have demonstrated 60–70% timeline reductions and enhanced clinical trial efficiency, challenges remain in hallucination mitigation, bias management, and regulatory validation. This assessment highlights transformative opportunities while addressing critical implementation barriers for widespread pharmaceutical adoption.
{"title":"Persona-driven generative AI in pharmaceuticals","authors":"Yun Wan , Makoto Nakayama , Cesar Floyd Aldana , Frank Alvino","doi":"10.1016/j.drudis.2025.104520","DOIUrl":"10.1016/j.drudis.2025.104520","url":null,"abstract":"<div><div>Persona-driven generative artificial intelligence (GenAI) represents a transformative approach to pharmaceutical innovation, providing structured frameworks that enhance AI–human collaboration across drug development. We examine recent applications (2023–2025) spanning target identification, clinical development, regulatory intelligence, and patient communication. Key developments include AlphaFold 3’s protein structure prediction breakthroughs, regulatory validation of digital twin methodologies, and AI-powered regulatory intelligence systems. Using contextual priming and specialized domain expertise, personas significantly improve GenAI performance in pharmaceutical contexts. Although these tools have demonstrated 60–70% timeline reductions and enhanced clinical trial efficiency, challenges remain in hallucination mitigation, bias management, and regulatory validation. This assessment highlights transformative opportunities while addressing critical implementation barriers for widespread pharmaceutical adoption.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 12","pages":"Article 104520"},"PeriodicalIF":7.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145436688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Endometrial cyclic remodeling and decidualization are critical physiological processes for female reproductive function and are profoundly influenced by mitochondrial homeostasis. Mitochondrial homeostasis is maintained through the mitochondrial quality control system, which precisely regulates mitochondrial energy metabolism via peroxisome proliferator-activated receptor-gamma (PPARγ) coactivator-1 alpha (PGC-1α)–nuclear respiratory factor (NRF)1/2-mediated biogenesis, mitofusin (MFN)1/2–optic atrophy (OPA1)-dependent fusion, dynamin-related protein (DRP)1-regulated fission, and PTEN-induced putative kinase 1 (PINK1)–Parkin-executed mitophagy. Dysregulation of this system caused by infection, endocrine disruption, or iatrogenic injury can alter or reprogram endometrial energy metabolism, disrupt immune balance, and promote fibrosis and abnormal proliferation, leading to various endometrial diseases and impaired fertility. This review systematically summarizes recent research advances on mitochondrial homeostasis in endometrial physiology and pathology, and its emerging role as a therapeutic target, aiming to provide insights and references for therapeutic strategies against endometrial diseases.
{"title":"Mitochondrial homeostasis: A key regulator in endometrial physiology and pathology","authors":"Keke Zhang , Enfeng Zhang , Kun Wu , Wenxiu Cheng , Shaobin Wei","doi":"10.1016/j.drudis.2025.104519","DOIUrl":"10.1016/j.drudis.2025.104519","url":null,"abstract":"<div><div>Endometrial cyclic remodeling and decidualization are critical physiological processes for female reproductive function and are profoundly influenced by mitochondrial homeostasis. Mitochondrial homeostasis is maintained through the mitochondrial quality control system, which precisely regulates mitochondrial energy metabolism via peroxisome proliferator-activated receptor-gamma (PPARγ) coactivator-1 alpha (PGC-1α)–nuclear respiratory factor (NRF)1/2-mediated biogenesis, mitofusin (MFN)1/2–optic atrophy (OPA1)-dependent fusion, dynamin-related protein (DRP)1-regulated fission, and PTEN-induced putative kinase 1 (PINK1)–Parkin-executed mitophagy. Dysregulation of this system caused by infection, endocrine disruption, or iatrogenic injury can alter or reprogram endometrial energy metabolism, disrupt immune balance, and promote fibrosis and abnormal proliferation, leading to various endometrial diseases and impaired fertility. This review systematically summarizes recent research advances on mitochondrial homeostasis in endometrial physiology and pathology, and its emerging role as a therapeutic target, aiming to provide insights and references for therapeutic strategies against endometrial diseases.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 12","pages":"Article 104519"},"PeriodicalIF":7.5,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145407674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-28DOI: 10.1016/j.drudis.2025.104518
Julien Delile , Srayanta Mukherjee , Judith Mueller , Iya Khalil , Leonid Zhukov , Christoph Meier
During the past decade, AI has evolved rapidly. Within the field, there has been particular innovation in the area of foundation models -- general-purpose AI algorithms that can be adapted to a broad range of tasks. Recently, researchers have started exploring how these foundation models can be applied to pharmaceutical R&D. In this review, we survey the landscape of foundation models in drug discovery research. We show that, starting in 2022, the number of foundation models has been growing extremely rapidly, with >200 such models published to date. We demonstrate that these cover a broad range of applications, including target discovery, molecular property optimization, preclinical applications and others. We also discuss what foundation-model-powered drug discovery could look like in the future.
{"title":"Foundation models in drug discovery: Phenomenal growth today, transformative potential tomorrow?","authors":"Julien Delile , Srayanta Mukherjee , Judith Mueller , Iya Khalil , Leonid Zhukov , Christoph Meier","doi":"10.1016/j.drudis.2025.104518","DOIUrl":"10.1016/j.drudis.2025.104518","url":null,"abstract":"<div><div>During the past decade, AI has evolved rapidly. Within the field, there has been particular innovation in the area of foundation models -- general-purpose AI algorithms that can be adapted to a broad range of tasks. Recently, researchers have started exploring how these foundation models can be applied to pharmaceutical R&D. In this review, we survey the landscape of foundation models in drug discovery research. We show that, starting in 2022, the number of foundation models has been growing extremely rapidly, with >200 such models published to date. We demonstrate that these cover a broad range of applications, including target discovery, molecular property optimization, preclinical applications and others. We also discuss what foundation-model-powered drug discovery could look like in the future.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 12","pages":"Article 104518"},"PeriodicalIF":7.5,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145407692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-28DOI: 10.1016/j.drudis.2025.104517
Yajie Xu , Zhijin Yan , Na Li , Jiaqi Tang , Zhice Xu
Studies on fetal-originated diseases have emerged as a pivotal biomedical frontier. This article first redefines birth defects into two categories, adding functional birth defects innovatively. Following comprehensively reviewing the progress in the study of prenatal influence and mechanisms, new research directions are indicated. Future predictive models, which integrate maternal health data with epigenetic profiles and genetic markers, have the potential to identify high-risk individuals early in life. As scientific progress in this field is explored, the pursuit of innovative solutions not only adds knowledge but also heralds a new era of early prevention of cardiovascular/metabolic diseases originating before birth.
{"title":"New visions and research trends in fetal-originated adult cardiovascular and metabolic diseases","authors":"Yajie Xu , Zhijin Yan , Na Li , Jiaqi Tang , Zhice Xu","doi":"10.1016/j.drudis.2025.104517","DOIUrl":"10.1016/j.drudis.2025.104517","url":null,"abstract":"<div><div>Studies on fetal-originated diseases have emerged as a pivotal biomedical frontier. This article first redefines birth defects into two categories, adding functional birth defects innovatively. Following comprehensively reviewing the progress in the study of prenatal influence and mechanisms, new research directions are indicated. Future predictive models, which integrate maternal health data with epigenetic profiles and genetic markers, have the potential to identify high-risk individuals early in life. As scientific progress in this field is explored, the pursuit of innovative solutions not only adds knowledge but also heralds a new era of early prevention of cardiovascular/metabolic diseases originating before birth.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 12","pages":"Article 104517"},"PeriodicalIF":7.5,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145407679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BET inhibitors (BETi), especially those targeting BRD4, show promising preclinical activity against pediatric sarcomas by disrupting oncogenic transcription. This systematic review of 26 studies highlights the anti-proliferative and pro-apoptotic effects of BETi across five pediatric sarcoma types. In vivo data show a decrease in tumor growth, with better results when combined with other therapies. This systematic review revealed that, whereas early investigations mostly rely on pan-BETi, recent studies focus on newer and more specific agents. Accordingly, we reported that ABBV-744 and RVX-208, which selectively target the BD2 domain, and GNE-987, a specific BRD4 degrader, are the most promising inhibitors. However, ABBV-075, a pan-BETi, also exhibits high efficacy, being effective at low doses. Nevertheless, translating these experimental findings into clinical practice remains difficult because of resistance, toxicity, and inconsistent responses. Future approaches include using biomarkers for patient selection, developing isoform-specific BETi, and designing rational combination therapies to enhance treatment for these aggressive pediatric cancers.
{"title":"Inhibition of bromodomain and extra-terminal motif (BET) proteins in pediatric sarcoma: A systematic review of in vitro and in vivo studies","authors":"Erika Ferraro , Elisa Macrì , Clemens Zwergel , Chiara Lambona , Giovanni Barillari , Cinzia Marchese , Franco Locatelli , Rossella Rota , Matteo Cassandri , Silvia Pomella","doi":"10.1016/j.drudis.2025.104516","DOIUrl":"10.1016/j.drudis.2025.104516","url":null,"abstract":"<div><div>BET inhibitors (BETi), especially those targeting BRD4, show promising preclinical activity against pediatric sarcomas by disrupting oncogenic transcription. This systematic review of 26 studies highlights the anti-proliferative and pro-apoptotic effects of BETi across five pediatric sarcoma types. <em>In vivo</em> data show a decrease in tumor growth, with better results when combined with other therapies. This systematic review revealed that, whereas early investigations mostly rely on pan-BETi, recent studies focus on newer and more specific agents. Accordingly, we reported that ABBV-744 and RVX-208, which selectively target the BD2 domain, and GNE-987, a specific BRD4 degrader, are the most promising inhibitors. However, ABBV-075, a pan-BETi, also exhibits high efficacy, being effective at low doses. Nevertheless, translating these experimental findings into clinical practice remains difficult because of resistance, toxicity, and inconsistent responses. Future approaches include using biomarkers for patient selection, developing isoform-specific BETi, and designing rational combination therapies to enhance treatment for these aggressive pediatric cancers.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 12","pages":"Article 104516"},"PeriodicalIF":7.5,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145399322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-27DOI: 10.1016/j.drudis.2025.104515
Tammy S.Y. Yim , Carlos Cifuentes-González , Rupesh Agrawal , Hazel H. Oon
In this scoping review, we highlight advances in small-molecule immunotherapeutics for non-infectious uveitis (NIU), a sight-threatening inflammatory disease. Unlike traditional corticosteroids and biologics, emerging small molecules promise enhanced ocular penetration and precise intracellular modulation. Analysing randomised trials, observational studies, and animal models, we identified 16 drug classes and 31 novel compounds. Notably, new-generation calcineurin inhibitors, Janus kinase (JAK) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, corticosteroids, and reactive aldehyde species (RASP) inhibitors demonstrated encouraging clinical efficacy. These agents could redefine treatment paradigms by minimising systemic toxicity and overcoming current therapeutic limitations. However, larger studies are needed to establish their long-term safety and effectiveness across diverse NIU patient populations.
{"title":"Evolving landscape of small-molecule immunotherapeutics for uveitis: a scoping review","authors":"Tammy S.Y. Yim , Carlos Cifuentes-González , Rupesh Agrawal , Hazel H. Oon","doi":"10.1016/j.drudis.2025.104515","DOIUrl":"10.1016/j.drudis.2025.104515","url":null,"abstract":"<div><div>In this scoping review, we highlight advances in small-molecule immunotherapeutics for non-infectious uveitis (NIU), a sight-threatening inflammatory disease. Unlike traditional corticosteroids and biologics, emerging small molecules promise enhanced ocular penetration and precise intracellular modulation. Analysing randomised trials, observational studies, and animal models, we identified 16 drug classes and 31 novel compounds. Notably, new-generation calcineurin inhibitors, Janus kinase (JAK) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, corticosteroids, and reactive aldehyde species (RASP) inhibitors demonstrated encouraging clinical efficacy. These agents could redefine treatment paradigms by minimising systemic toxicity and overcoming current therapeutic limitations. However, larger studies are needed to establish their long-term safety and effectiveness across diverse NIU patient populations.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 12","pages":"Article 104515"},"PeriodicalIF":7.5,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145399229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-25DOI: 10.1016/j.drudis.2025.104514
Xingyu Yin, Huangliang Shu, Danni Wang, Qidong You, Qiuyue Zhang, Lei Wang
Heat shock protein 90 (HSP90) plays a critical role in maintaining cellular proteostasis by facilitating protein folding and maturation. Although HSP90 inhibitors have been extensively studied in cancer, their potential in non-oncological diseases remains underexplored and merits systematic discussion. This review focuses on the pivotal roles of HSP90 inhibitors in treating non-oncological diseases, specifically viral and fungal infections, inflammatory disorders, and neurodegenerative diseases. We analyze recent advances in inhibitor optimization, the relevant signaling pathways, and mechanistic insights into HSP90–client protein interactions. We propose strategic approaches to overcome challenges in the clinical translation of HSP90 inhibitors for non-oncological indications. Our analysis underscores the need for optimized inhibitor design and deeper mechanistic understanding to unlock the full therapeutic potential of HSP90 inhibitors beyond oncology.
{"title":"HSP90 inhibitors beyond oncology: optimization and mechanism insights in non-oncological diseases","authors":"Xingyu Yin, Huangliang Shu, Danni Wang, Qidong You, Qiuyue Zhang, Lei Wang","doi":"10.1016/j.drudis.2025.104514","DOIUrl":"10.1016/j.drudis.2025.104514","url":null,"abstract":"<div><div>Heat shock protein 90 (HSP90) plays a critical role in maintaining cellular proteostasis by facilitating protein folding and maturation. Although HSP90 inhibitors have been extensively studied in cancer, their potential in non-oncological diseases remains underexplored and merits systematic discussion. This review focuses on the pivotal roles of HSP90 inhibitors in treating non-oncological diseases, specifically viral and fungal infections, inflammatory disorders, and neurodegenerative diseases. We analyze recent advances in inhibitor optimization, the relevant signaling pathways, and mechanistic insights into HSP90–client protein interactions. We propose strategic approaches to overcome challenges in the clinical translation of HSP90 inhibitors for non-oncological indications. Our analysis underscores the need for optimized inhibitor design and deeper mechanistic understanding to unlock the full therapeutic potential of HSP90 inhibitors beyond oncology.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 12","pages":"Article 104514"},"PeriodicalIF":7.5,"publicationDate":"2025-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145457397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-24DOI: 10.1016/j.drudis.2025.104511
Kankan Roy, Bapi Gorain
Micro- and macrovascular complications associated with diabetes patients complicate the healing process of wounds, often leading to limb amputations. Lack of proper treatment strategies generates alarming conditions, where the literature reveals that 5′-adenosine monophosphate-activated protein kinase (AMPK) plays an important role in maintaining homeostasis of cellular energy and insulin signaling sensitivity, which alter multiple cellular processes, including angiogenesis, communication, cell migration, and proliferation. Thus, this review focuses on the current understanding of the physiological and pathological roles of AMPK in the diabetic wound environment, which facilitates the healing process via different pathways involved in molecular and physiological regulation.
{"title":"Targeting AMPK signaling in diabetic wounds facilitates the healing process","authors":"Kankan Roy, Bapi Gorain","doi":"10.1016/j.drudis.2025.104511","DOIUrl":"10.1016/j.drudis.2025.104511","url":null,"abstract":"<div><div>Micro- and macrovascular complications associated with diabetes patients complicate the healing process of wounds, often leading to limb amputations. Lack of proper treatment strategies generates alarming conditions, where the literature reveals that 5′-adenosine monophosphate-activated protein kinase (AMPK) plays an important role in maintaining homeostasis of cellular energy and insulin signaling sensitivity, which alter multiple cellular processes, including angiogenesis, communication, cell migration, and proliferation. Thus, this review focuses on the current understanding of the physiological and pathological roles of AMPK in the diabetic wound environment, which facilitates the healing process via different pathways involved in molecular and physiological regulation.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 12","pages":"Article 104511"},"PeriodicalIF":7.5,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145457325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号